Establishment Labs is the industry's growth leader with 45% year-over-year revenue expansion and strong price momentum, but negative free cash flow, a 16% short interest, and a stock that has reached its near-term target with negative downside asymmetry make this a high-risk setup where the growth story is not yet matched by financial sustainability.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Negative Free Cash Flow Sustainability→Stable
- High Short Interest Skepticism→Stable
- +1 more pillar — see the Why tab for full reasoning
Establishment Labs Holdings Inc (ESTA) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $89.25 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source silicone supplier.
Establishment Labs sells Motiva silicone gel-filled breast implants registered in over 100 countries, receiving FDA PMA approval in September 2024 and beginning U.S. commercial sales in October 2024. The majority of revenue comes from Motiva Implant sales through exclusive... Read more
Sell if holding. Analyst target reached at $89.25 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source silicone supplier. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.1/10, high confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About Establishment Labs Holdings Inc
About Establishment Labs Holdings Inc
Motiva Implants—Establishment Labs' line of silicone gel-filled breast implants launched commercially in October 2010—received FDA PMA approval in September 2024, the first such approval for a new breast implant since 2013, enabling U.S. commercial sales that began in October 2024. The Motiva portfolio is registered in over 100 countries and includes five product families spanning Round, Ergonomix, Ergonomix2, Anatomical TrueFixation, and Flora Tissue Expander variants, with a catalog exceeding 1,000 product variations.
Establishment Labs generates the majority of revenue from Motiva Implant unit sales to surgeons and hospitals, distributed through exclusive country-level distributors and a direct sales force. The company introduced Preservé—a minimally invasive tissue-preserving augmentation technology—in Brazil in February 2025, with additional country launches through 2025 and a full U.S. launch planned for 2026. The Mia Femtech procedure system, which enables breast augmentation under local anesthesia through smaller incisions, has been offered in multiple countries since April 2023. Competitors in the U.S. market include Sientra, Allergan, and Mentor—the only three competitor companies currently approved to market silicone breast implants in the United States—and Motiva's 5-year IDE study data reports lower capsular contracture and rupture rates versus published 10-year data from those peers.
Show full overview
The company discloses reliance on a single-source, third-party supplier for medical-grade long-term implantable silicone, the primary raw material across all Motiva product families. Any interruption to this supply or price increase could weigh on manufacturing of all five product families simultaneously. An inventory funding agreement signed in May 2025 with RTW Investments to finance silicone raw material purchases—with two $5 million tranches drawn in June and September 2025—reflects the capital management demands of this single-input dependency.
See also: Healthcare · Medical Devices
From Establishment Labs Holdings Inc's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Establishment Labs Holdings Inc
Latest news
- NEWS Establishment Labs Set To Join Russell 2000 Index, Effective June 29 — benzinga Jun 25, 2026 positive
- NEWS BTIG Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $90 — benzinga May 7, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga May 6, 2026 neutral
- NEWS Establishment Labs Hldgs Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga May 6, 2026 neutral
Generated 2026-07-06T04:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductMotiva Implants10-K Item 1: 'the majority of our revenue has been generated from sales of our Motiva Implants'
- HIGHSuppliersingle-source silicone supplier10-K Item 1A: 'We rely on a single-source, third-party supplier for medical-grade long-term implantable silicone, which is the primary raw material used in our Motiva Implants.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $89.25 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single-source silicone supplier. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $83.00. Score 5.1/10, high confidence.
Take-profit target: $88.69 (-0.6% upside). Prior stop was $83.00. Stop-loss: $83.00.
Concentration risk — Supplier: single-source silicone supplier; Analyst target reached - limited upside remaining; Near 52-week high (1.4% away).
Establishment Labs Holdings Inc trades at a P/E of N/A (forward 1190.0). TrendMatrix value score: 2.8/10. Verdict: Sell.
15 analysts cover ESTA with a consensus score of 4.2/5. Average price target: $91.
What does Establishment Labs Holdings Inc do?Establishment Labs sells Motiva silicone gel-filled breast implants registered in over 100 countries, receiving FDA PMA...
Establishment Labs sells Motiva silicone gel-filled breast implants registered in over 100 countries, receiving FDA PMA approval in September 2024 and beginning U.S. commercial sales in October 2024. The majority of revenue comes from Motiva Implant sales through exclusive distributors and a direct sales force across five product families.